Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration

Addiction Biology

Volumn 15, Issue 4, 2010, Pages 424-433

  Carnicella, Sebastien ^a,b,d   He, Dao Yao ^a   Yowell, Quinn V ^a   Glick, Stanley D ^c   Ron, Dorit ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

18 Methoxycoronaridine; addiction; ethanol self administration; GDNF; ibogaine; noribogaine

Indexed keywords

18 METHOXYCORONARIDINE; ALCOHOL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IBOGAINE; MESSENGER RNA; NORIBOGAINE;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELF ADMINISTRATION; HUMAN; HUMAN CELL; MALE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; VENTRAL TEGMENTUM;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; CELL LINE, TUMOR; CONDITIONING, OPERANT; GENE EXPRESSION; HUMANS; IBOGAINE; MALE; MOTIVATION; RATS; RATS, LONG-EVANS; RNA, MESSENGER; SELF ADMINISTRATION; VENTRAL TEGMENTAL AREA;

EID: 78649468794     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2010.00251.x     Document Type: Article

References (52)

1. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J, (2000) Ibogaine in acute opioid withdrawal. An open label case series. Ann N Y Acad Sci 909: 257-259.
2. Alper KR, Lotsof HS, Kaplan CD, (2008) The ibogaine medical subculture. J Ethnopharmacol 115: 9-24.
3. Baumann MH, Rothman RB, Pablo JP, Mash DC, (2001) In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 297: 531-539.
4. Cappendijk SL, Dzoljic MR, (1993) Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 241: 261-265.
5. Cappendijk SL, Fekkes D, Dzoljic MR, (1994) The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. Behav Brain Res 65: 117-119.
6. Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D, (2009a) Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. Biol Psychiatry 66: 146-153.
7. Carnicella S, Amamoto R, Ron D, (2009b) Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 43: 35-43.
8. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D, (2008) GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A 105: 8114-8119.
9. Carnicella S, Ron D, (2009) GDNF-a potential target to treat addiction. Pharmacol Ther 122: 9-18.
10. Garbutt JC, (2009) The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 36: S15-S23. quiz S24- 25.
11. Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH, (1996a) 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res 719: 29-35.
12. Glick SD, Kuehne ME, Raucci J, Wilson TE, Larson D, Keller RW, Jr, Carlson JN, (1994) Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 657: 14-22.
13. Glick SD, Maisonneuve IS, (1998) Mechanisms of anti-addictive actions of ibogaine. Ann N Y Acad Sci 844: 214-226.
14. Glick SD, Maisonneuve IM, Kitchen BA, (2002a) Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur J Pharmacol 448: 185-191.
15. Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW, (2002b) Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 438: 99-105.
16. Glick SD, Maisonneuve IM, Szumlinski KK, (2000) 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci 914: 369-386.
17. Glick SD, Pearl SM, Cai J, Maisonneuve IM, (1996b) Ibogaine-like effects of noribogaine in rats. Brain Res 713: 294-297.
18. Glick SD, Ramirez RL, Livi JM, Maisonneuve IM, (2006) 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. Eur J Pharmacol 537: 94-98.
19. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN, (1992) Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology 31: 497-500.
20. Glick SD, Sell EM, Maisonneuve IM, (2008) Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur J Pharmacol 599: 91-95.
21. He DY, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D, (2005) Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25: 619-628.
22. He DY, Ron D, (2006) Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 20: 2420-2422.
23. He DY, Ron D, (2008) Glial cell line-derived neurotrophic factor reverses ethanol-mediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90. J Biol Chem 283: 12811-12818.
24. Jhou TC, Fields HL, Baxter MG, Saper CB, Holland PC, (2009) The rostromedial tegmental nucleus (RMTg), a GABAergic afferent to midbrain dopamine neurons, encodes aversive stimuli and inhibits motor responses. Neuron 61: 786-800.
25. Johnson BA, (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75: 34-56.
26. Keppel G, (1991) Design and Analysis: A Researcher's Handbook, third edn Upper, Saddla River, NJ: Prentice Hall.
27. Klink R, De Kerchove d'Exaerde A, Zoli M, Changeux JP, (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21: 1452-1463.
28. Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L, (2008) Acute toxicity of ibogaine and noribogaine. Medicina (Kaunas) 44: 984-988.
29. Maas U, Strubelt S, (2006) Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses 67: 960-964.
30. Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V, (2008) Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 27: 181-194.
31. Maisonneuve IM, Glick SD, (2003) Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 75: 607-618.
32. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, Sanchez-Ramos J, (1998) Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 844: 274-292.
33. Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M, (2000) Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci 914: 394-401.
34. Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL, (1995) Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci 57: PL45-PL50.
35. Molinari HH, Maisonneuve IM, Glick SD, (1996) Ibogaine neurotoxicity: a re-evaluation. Brain Res 737: 255-262.
36. Nishikawa T, Fage D, Scatton B, (1986) Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res 373: 324-336.
37. O'Hearn E, Molliver ME, (1993) Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55: 303-310.
38. O'Hearn E, Molliver ME, (1997) The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity. J Neurosci 17: 8828-8841.
39. Obach RS, Pablo J, Mash DC, (1998) Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos 26: 764-768.
40. Paxinos G, Watson C, (2007) The Rat Brain in Stereotaxic Coordinates, sixth edn San Diego: Academic Press.
41. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ, (2002) Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 82: 468-481.
42. Popik P, Layer RT, Skolnick P, (1995) 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 47: 235-253.
43. Quick MW, Ceballos RM, Kasten M, McIntosh JM, Lester RA, (1999) Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology 38: 769-783.
44. Rezvani AH, Overstreet DH, Lee YW, (1995) Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav 52: 615-620.
45. Rezvani AH, Overstreet DH, Yang Y, Maisonneuve IM, Bandarage UK, Kuehne ME, Glick SD, (1997) Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav 58: 615-619.
46. Sershen H, Hashim A, Lajtha A, (1994) Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol Biochem Behav 47: 13-19.
47. Sharpe LG, Jaffe JH, (1990) Ibogaine fails to reduce naloxone- precipitated withdrawal in the morphine-dependent rat. Neuroreport 1: 17-19.
48. Sheppard SG, (1994) A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 11: 379-385.
49. Smith DA, (1991) Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 23: 355-373.
50. Sweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J, (1995) Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology (Berl) 118: 369-376.
51. Vastag B, (2002) Addiction treatment strives for legitimacy. JAMA 288: 3099-3101.
52. Woodland C, Huang TT, Gryz E, Bendayan R, Fawcett JP, (2008) Expression, activity and regulation of CYP3A in human and rodent brain. Drug Metab Rev 40: 149-168.